AAPL 258.8189 0.2397% MSFT 439.14 -0.0432% NVDA 140.185 -0.025% GOOGL 196.0128 -0.0496% GOOG 197.54 -0.0152% AMZN 227.87 -0.5152% META 603.74 -0.6598% AVGO 245.6915 2.5081% TSLA 452.9125 -2.0264% TSM 204.19 -1.0372% LLY 797.2122 0.1938% V 320.96 0.0967% JPM 242.37 0.0248% UNH 509.62 0.6955% NVO 87.85 0.5494% WMT 92.38 -0.3237% LVMUY 132.91 0.4459% XOM 106.31 -0.0846% LVMHF 664.0 0.9119% MA 536.2159 0.0944%
Last update at 2024-12-26T18:53:00Z
Will Amphastar (AMPH) Beat Estimates Again in Its Next Earnings Report?
Fri 18 Oct 24, 04:10 PMImplied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options
Thu 03 Oct 24, 12:42 PMInsider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)
Sat 07 Sep 24, 05:43 AMAmphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
Wed 28 Aug 24, 08:10 PMAmphastar Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Fri 09 Aug 24, 10:38 AMCompared to Estimates, Amphastar (AMPH) Q2 Earnings: A Look at Key Metrics
Wed 07 Aug 24, 11:30 PM| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | 171.36M | 116.04M | 84.14M | 4.64M | 60.23M |
| Minority interest | 0.00000M | 0.00000M | 1.19M | -0.30600M | -2.43400M |
| Net income | 137.54M | 91.39M | 62.12M | 1.10M | 48.94M |
| Selling general administrative | 51.54M | 45.06M | 51.43M | 50.38M | 50.28M |
| Selling and marketing expenses | 28.85M | 21.53M | 17.49M | 14.78M | 12.83M |
| Gross profit | 351.12M | 248.86M | 199.74M | 143.34M | 131.92M |
| Reconciled depreciation | 35.78M | 28.74M | 26.75M | 25.18M | 21.12M |
| Ebit | 198.52M | 78.76M | 85.02M | 5.01M | -0.03900M |
| Ebitda | 240.29M | 107.50M | 111.78M | 30.19M | 21.08M |
| Depreciation and amortization | 41.78M | 28.74M | 26.75M | 25.18M | 21.12M |
| Non operating income net other | - | 9.21M | 14.93M | -5.94300M | 60.39M |
| Operating income | 196.99M | 78.76M | 43.13M | -14.22600M | -0.03900M |
| Other operating expenses | 447.41M | 391.49M | 367.88M | 338.89M | 322.40M |
| Interest expense | 27.16M | 1.85M | 0.89M | 0.37M | 0.12M |
| Tax provision | 34.45M | 23.48M | 20.63M | 3.54M | 13.72M |
| Interest income | 3.74M | 1.32M | 0.60M | 0.64M | 1.00M |
| Net interest income | -14.49400M | -0.52500M | -0.28400M | 0.27M | 0.88M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 31.83M | 23.48M | 20.63M | 3.54M | 13.72M |
| Total revenue | 644.39M | 498.99M | 437.77M | 349.85M | 322.36M |
| Total operating expenses | 154.13M | 141.36M | 129.85M | 132.39M | 131.96M |
| Cost of revenue | 293.27M | 250.13M | 238.03M | 206.51M | 190.43M |
| Total other income expense net | -25.62800M | 8.54M | 14.25M | -6.31700M | 60.27M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 135.29M | 91.39M | 63.51M | 1.10M | 46.51M |
| Net income applicable to common shares | - | 91.39M | 62.12M | 1.40M | 48.94M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1512.91M | 741.99M | 671.53M | 631.24M | 586.97M |
| Intangible assets | 610.08M | 34.17M | 35.56M | 36.67M | 37.52M |
| Earning assets | - | - | - | - | - |
| Other current assets | 9.58M | 7.56M | 7.27M | 6.78M | 9.54M |
| Total liab | 873.49M | 213.33M | 226.01M | 182.51M | 159.44M |
| Total stockholder equity | 639.42M | 528.66M | 445.52M | 402.31M | 381.37M |
| Deferred long term liab | - | - | 0.53M | 0.74M | 0.87M |
| Other current liab | 194.02M | 4.57M | 9.08M | 1.08M | 2.04M |
| Common stock | 0.00600M | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Capital stock | 0.00600M | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Retained earnings | 409.27M | 271.72M | 180.34M | 117.77M | 116.37M |
| Other liab | - | 21.93M | 22.72M | 18.66M | 13.72M |
| Good will | 3.22M | 3.13M | 3.31M | 3.94M | 3.63M |
| Other assets | - | 59.38M | 39.06M | 50.88M | 37.03M |
| Cash | 144.53M | 156.10M | 126.35M | 92.64M | 73.69M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 225.41M | 94.86M | 103.81M | 112.20M | 90.01M |
| Current deferred revenue | 1.61M | - | - | - | - |
| Net debt | 479.11M | -53.51600M | -21.69000M | -25.37200M | -7.06000M |
| Short term debt | 4.34M | 6.05M | 5.18M | 15.62M | 10.92M |
| Short long term debt | 0.44M | 3.05M | 2.20M | 12.26M | 7.74M |
| Short long term debt total | 623.64M | 102.58M | 104.66M | 67.27M | 66.62M |
| Other stockholder equity | 238.62M | 265.55M | 271.94M | 288.25M | 269.68M |
| Property plant equipment | - | 238.27M | 244.24M | 260.06M | 233.86M |
| Total current assets | 489.60M | 378.32M | 318.12M | 279.68M | 255.24M |
| Long term investments | 15.21M | 2.41M | 3.98M | - | - |
| Net tangible assets | - | 491.36M | 406.65M | 361.69M | 340.21M |
| Short term investments | 114.71M | 19.66M | 10.32M | 12.98M | 11.68M |
| Net receivables | 114.94M | 88.97M | 78.93M | 66.39M | 45.69M |
| Long term debt | 589.58M | 72.84M | 74.78M | 34.19M | 39.39M |
| Inventory | 105.83M | 103.58M | 92.81M | 96.83M | 110.50M |
| Accounts payable | 25.44M | 84.24M | 89.55M | 95.50M | 77.05M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 46.42M | 46.16M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -8.47800M | -8.62400M | -6.76500M | -3.72100M | -4.68700M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.00600M | 0.00600M | 0.00500M | 0.00500M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 271.72M | 180.34M | 117.77M | 116.37M |
| Treasury stock | - | -189.52400M | -150.47900M | -121.81200M | -97.62700M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 25.91M | 20.86M | 16.66M | 5.25M | 11.16M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 1023.31M | 363.67M | 353.41M | 351.55M | 331.73M |
| Capital lease obligations | 33.63M | 26.70M | 27.68M | 20.82M | 19.49M |
| Long term debt total | - | 72.84M | 74.78M | 34.19M | 39.39M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -546.29600M | -7.79200M | 1.40M | -1.14600M | -8.81500M |
| Change to liabilities | - | -0.73600M | 3.02M | 20.61M | -11.72000M |
| Total cashflows from investing activities | - | -32.77700M | -28.67200M | -36.41500M | -50.52700M |
| Net borrowings | - | -2.18800M | 30.36M | -0.88000M | -3.21100M |
| Total cash from financing activities | 454.09M | -26.43900M | -37.01800M | -2.24600M | -3.78300M |
| Change to operating activities | - | -5.00800M | 0.37M | -5.64600M | -6.21700M |
| Net income | 137.54M | 91.39M | 63.30M | 1.10M | 46.51M |
| Change in cash | -11.80200M | 29.75M | 32.08M | 18.96M | -12.65200M |
| Begin period cash flow | 156.33M | 126.59M | 94.51M | 75.55M | 88.20M |
| End period cash flow | 144.53M | 156.33M | 126.59M | 94.51M | 75.55M |
| Total cash from operating activities | 183.50M | 89.18M | 97.99M | 57.27M | 41.76M |
| Issuance of capital stock | - | - | - | 0.00000M | 18.30M |
| Depreciation | 41.78M | 28.74M | 26.75M | 25.18M | 21.12M |
| Other cashflows from investing activities | - | -0.95100M | -2.61200M | -1.41400M | -0.15700M |
| Dividends paid | 454.09M | 15.66M | 15.93M | 23.16M | - |
| Change to inventory | -1.72400M | -11.74600M | 1.26M | 15.30M | -41.10300M |
| Change to account receivables | -26.08600M | -10.13200M | -14.92100M | -20.16000M | 6.70M |
| Sale purchase of stock | -58.14400M | -39.90900M | -28.87300M | -24.42500M | -22.29100M |
| Other cashflows from financing activities | -14.10500M | 15.25M | -40.24400M | 23.06M | 6.99M |
| Change to netincome | - | 2.73M | 8.04M | 20.58M | 22.87M |
| Capital expenditures | 38.17M | 24.03M | 27.46M | 33.85M | 41.55M |
| Change receivables | - | -10.13200M | -14.92100M | -20.16000M | 6.70M |
| Cash flows other operating | - | -7.55900M | 13.81M | -1.68000M | 0.40M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 29.96M | 32.30M | 18.61M | -12.54800M |
| Change in working capital | -24.20900M | -32.17700M | -1.92400M | 9.13M | -51.74700M |
| Stock based compensation | 20.24M | 17.86M | 18.69M | 20.50M | 17.30M |
| Other non cash items | 20.73M | -0.87800M | -13.03100M | 0.24M | 1.04M |
| Free cash flow | 145.34M | 65.15M | 70.54M | 23.41M | 0.21M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AMPH Amphastar P |
-0.075 0.20% | 38.20 | 14.56 | - | 2.91 | 2.89 | 3.43 | 8.98 |
| ZTS Zoetis Inc |
0.35 0.22% | 165.06 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.04 0.14% | 28.78 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% | 141.27 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.02 0.15% | 13.15 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
11570 6th Street, Rancho Cucamonga, CA, United States, 91730
| Name | Title | Year Born |
|---|---|---|
| Dr. Ziping Luo Ph.D. | Chairman, Chief Scientist & COO | 1950 |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, Pres, CEO, Chief Scientific Officer & Director | 1947 |
| Mr. William J. Peters M.B.A. | CFO, Exec. VP of Fin., Treasurer & Director | 1968 |
| Mr. Jacob Liawatidewi M.B.A. | Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director | 1974 |
| Mr. Rong Zhou M.S. | Exec. VP of Production Center | 1959 |
| Dan Dischner M.B.A. | VP of HR & Corp. Communication | NA |
| Tony Marrs M.B.A., M.P.H. | Sr. VP of Regulatory Affairs & Clinical Operations | NA |
| Mr. Peter Langosh | VP of Operational Improvement and VP of Internal Audit | 1953 |
| Dr. Ziping Luo Ph.D. | Chairman of the Board, Chief Scientist & COO | 1950 |
| Dr. Yongfeng Zhang Ph.D. | Co-Founder, President, CEO, Chief Scientific Officer & Director | 1947 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...